Peregrine Asset Advisers Inc. lessened its position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 95.1% in the 1st quarter, Holdings Channel reports. The firm owned 3,019 shares of the exchange traded fund’s stock after selling 58,205 shares during the period. Peregrine Asset Advisers Inc.’s holdings in SPDR S&P Biotech ETF were worth $386,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Financial Life Planners bought a new position in shares of SPDR S&P Biotech ETF during the first quarter worth $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of SPDR S&P Biotech ETF in the 4th quarter valued at $27,000. Intesa Sanpaolo Wealth Management bought a new stake in shares of SPDR S&P Biotech ETF in the 4th quarter valued at $30,000. SHP Wealth Management acquired a new stake in SPDR S&P Biotech ETF during the 4th quarter worth $31,000. Finally, Legacy Wealth Managment LLC ID acquired a new stake in SPDR S&P Biotech ETF during the 4th quarter worth $32,000.
SPDR S&P Biotech ETF Trading Up 2.5%
XBI stock opened at $160.46 on Friday. SPDR S&P Biotech ETF has a 1-year low of $83.02 and a 1-year high of $160.82. The firm has a market cap of $11.09 billion, a PE ratio of 11.47 and a beta of 0.81. The business’s 50-day moving average price is $136.95 and its two-hundred day moving average price is $129.75.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Featured Articles
- Five stocks we like better than SPDR S&P Biotech ETF
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
